Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
European Journal of Haematology|December 24, 2022
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myelomaOded Shamriz, Elchanan Parnasa, Limor Rubin, et al.
Cancers|March 29, 2023
Venetoclax in Relapse/Refractory AL Amyloidosis-A Multicenter International Retrospective Real-World StudyEyal Lebel, Efstathios Kastritis, Giovanni Palladini, et al.
Leukemia & Lymphoma|February 15, 2014
Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemiaJacob Vine, Sara Bar Cohen, Rosa Ruchlemer, et al.
Seminars in Hematology|April 26, 2023
Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related AmyloidosisGiampaolo Merlini, Shayna Sarosiek, Giulia Benevolo, et al.
Leukemia Research|July 1, 2022
Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center studyAvraham Frisch, Shlomzion Aumann, Tsila Zuckerman, et al.
American Journal of Hematology|April 1, 2018
Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective studyYael C Cohen, Avi Saranga, Moshe E Gatt, et al.
British Journal of Haematology|November 17, 2015
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational studyEli Muchtar, Moshe E Gatt, Ory Rouvio, et al.
Cancers|November 13, 2025
High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T)Ariela Arad, Maya Katz, Eyal Lebel, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2020
Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life StudyEfrat Luttwak, Moshe E Gatt, Eyal Lebel, et al.
Annals of Hematology|March 21, 2020
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry studyYael C Cohen, Hila Magen, Noa Lavi, et al.
Pageof 9